| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 52125-0018-02 | 52125-0018 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jul 18, 2012 | Jul 19, 2013 | No Longer Used |
| 52125-0833-01 | 52125-0833 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Feb 13, 2014 | Feb 11, 2015 | No Longer Used | |
| 00603-3633-21 | 00603-3633 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 22, 2006 | Feb 28, 2018 | No Longer Used |
| 42291-0457-30 | 42291-0457 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 17, 2025 | In Use | |
| 00013-8717-62 | 00013-8717 | Dexrazoxane | Zinecard | 250.0 mg/25mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | May 26, 1995 | Apr 30, 2021 | No Longer Used |
| 00078-0241-15 | 00078-0241 | Cyclosporine | Sandimmune | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Mar 2, 1990 | In Use | |
| 70518-2895-00 | 70518-2895 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sep 25, 2020 | In Use | |
| 16714-0834-01 | 16714-0834 | Palonosetron | Palonosetron | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 29, 2018 | In Use | |
| 51079-0321-20 | 51079-0321 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jul 13, 2015 | Jun 30, 2019 | No Longer Used |
| 57881-0444-01 | 57881-0444 | Ondansetron | Zuplenz | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 8, 2014 | In Use | |
| 53217-0300-10 | 53217-0300 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | In Use | |
| 55111-0172-30 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2007 | In Use | |
| 72603-0402-01 | 72603-0402 | Pegflilgrastim-fpgk | STIMUFEND | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Dec 29, 2025 | In Use | |
| 42043-0390-40 | 42043-0390 | Granisetron Hydrochloride | Granisetron Hydrochloride | 1.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2016 | In Use | |
| 65162-0750-03 | 65162-0750 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 2, 2015 | In Use | |
| 23155-0196-31 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan 18, 2013 | In Use | |
| 87441-0088-01 | 87441-0088 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 8, 2026 | In Use | |
| 23155-0196-42 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan 18, 2013 | In Use | |
| 55390-0053-01 | 55390-0053 | Leucovorin Calcium | Leucovorin Calcium | Ancillary Therapy | Chemoprotective | Antidote | May 1, 1996 | Apr 30, 2014 | No Longer Used | ||
| 00409-3414-11 | 00409-3414 | Metoclopramide | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Aug 26, 2024 | In Use | |
| 68001-0246-04 | 68001-0246 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 13, 2018 | In Use | |
| 00006-4119-03 | 00006-4119 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL, 40.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | In Use | |
| 55390-0266-01 | 55390-0266 | Mesna | Mesna | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Jan 9, 2004 | Jul 31, 2012 | No Longer Used | ||
| 68788-9402-02 | 68788-9402 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 23, 2017 | In Use | |
| 68084-0220-11 | 68084-0220 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 16, 2012 | In Use |
Found 12482 results — Export these results
Home